Cipla Limited

NSE: CIPLA · Healthcare · Lot size: 375

OverviewOption ChainOI AnalysisFII / DIIMax Pain

Cipla Limited Share Price & Analysis

₹1,416Updated 22 Jul 2026, 03:30 pm IST
LTP
₹1,416
—
Open
₹1,423
High
₹1,423
Low
₹1,395.7
Close
₹1,432.5
52W High
₹1,673
52W Low
₹1,166
Volume
1722K
Lot Size
375
Sector
Healthcare
Market Cap
₹1.1L Cr
Face Value
₹2
Large CapNIFTY 100NIFTY 200NIFTY 50NIFTY 500

Price Chart

Fundamentals

P/E
30.1
Sector P/E
54.4
P/B
3.32
EPS
₹56.29
ROE
11.6%
ROCE
15.5%
D/E Ratio
0.02
Div Yield
0.92%
Book Value
₹426
+

Strengths

  • ✓Efficient capital deployment (ROCE 15.5%)
  • ✓Attractively valued vs sector (P/E 30.1x vs industry 54.4x)
  • ✓Virtually debt-free

Peer Comparison

CompanyCMPMkt CapP/EP/BROE %ROCE %D/E
SUNPHARMA
Sun Pharmaceutical Industries Limited
₹1,944
₹4.6L Cr37.35.591620.50.07
DIVISLAB
Divi's Laboratories Limited
₹7,388
₹1.9L Cr73.411.7116.5220.01
TORNTPHARM
Torrent Pharmaceuticals Limited
₹5,040
₹1.6L Cr73.620.3227.415.20.33
APOLLOHOSP
Apollo Hospitals Enterprise Limited
₹8,939
₹1.3L Cr64.913.5622.117.90.88
ZYDUSLIFE
Zydus Lifesciences Limited
₹1,123
₹1.1L Cr214.1721.221.10.38
LUPIN
Lupin Limited
₹2,405
₹1.1L Cr19.64.928.729.90.32
MAXHEALTH
Max Healthcare Institute Limited
₹1,080
₹1.1L Cr71.59.8214.714.70.33

Showing 7 peers in the same sector · Sorted by market cap

Shareholding Pattern

CIPLA · as of Mar 2026

Promoters29.20%
FII26.28%▼0.37
DII27.89%▲0.40
Public16.36%▼0.07
Govt0.26%▲0.03
CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters33.46%33.46%30.91%30.93%29.19%29.20%
FII25.73%25.82%27.82%28.80%26.65%26.28%
DII24.05%24.15%24.66%23.95%27.49%27.89%
Public16.53%16.36%16.40%16.11%16.43%16.36%
Govt0.21%0.21%0.21%0.21%0.23%0.26%

Corporate Events

To consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended 30th June, 2026.In terms of the Company's Code of Conduct for prevention of Insider Trading, the 'Trading window' for dealing in the s

Results22 Jul 2026

Dividend - Rs 13 Per Share

Dividend4 Jun 2026

To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters

Dividend12 May 2026

Dividend - Rs 13 Per Share/Special Dividend - Rs 3 Per Share

Dividend26 Jun 2025

Dividend - Rs 13 Per Share

Dividend1 Aug 2024

Dividend - Rs 8.50 Per Share

Dividend20 Jul 2023

Latest News

All news →

Cipla announces change in management team

Cipla Limited has announced a change in its management team, as per a regulatory filing with the NSE. Leadership transitions can impact strategic direction and execution in pharma firms. Such changes often trigger investor reassessment of governance and future outlook. 📊 *STOCKS:* CIPLA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #ManagementChange

NSE Filing16 Jun
High Impact

Cipla to host analyst and investor meet

*Cipla to host analyst and investor meet* to discuss business updates and strategy. The event is scheduled as per a recent NSE filing. No major financial announcements or guidance revision were disclosed. Investors await key insights on growth and margins. 📊 *STOCKS:* CIPLA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Cipla

NSE Filing8 Jul
Low Impact

USFDA taps Zydus, Cipla to ease drug shortage

*USFDA taps Zydus, Cipla to ease drug shortage.* The USFDA has identified Zydus Lifesciences and Cipla as key suppliers to address the **ifosfamide** shortage in the US market. This presents a near-term export opportunity for both companies amid rising global demand. Regulatory approvals from USFDA could boost volumes and margins. 📊 *STOCKS:* ZYDUSLIFE, CIPLA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma

Medical Dialogues26 Jun
Medium Impact

Cipla updates ESG rating in corporate filing

*Cipla updates ESG rating in corporate filing.* The company disclosed its latest ESG performance metrics in a regulatory filing. No financial figures or material events were announced. The update reflects ongoing sustainability disclosures. 📊 *STOCKS:* CIPLA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ESG

NSE Filing25 Jun
Low Impact

Cipla grants stock options and SARs to employees

*Cipla grants stock options and SARs to employees*. Cipla Limited has announced the grant of stock options and employee stock appreciation rights (SARs) to its employees. The move is part of the company’s employee incentive program to retain and motivate talent. Specific numbers of options granted and eligible employees were not disclosed. 📊 *STOCKS:* CIPLA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #StockOptions

NSE Filing16 Jun
Low Impact

Cipla updates on Verna manufacturing facility in Goa

*Cipla updates on Verna manufacturing facility in Goa.* The company provided general corporate updates regarding its facility in Verna, Goa. No financial or operational specifics were disclosed. Such routine updates typically have limited market impact. 📊 *STOCKS:* CIPLA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma

NSE Filing11 Jun
Low Impact

Financials

Quarterly Results

MetricDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
Revenue
₹7.1K Cr
▼6.8%
₹7.6K Cr
▲9.1%
₹7.0K Cr
▲3.4%
₹6.7K Cr
▼4.8%
₹7.1K Cr
▲0.3%
₹7.1K Cr
▲5.3%
₹6.7K Cr
▲8.6%
₹6.2K Cr
Op. Profit
₹1.3K Cr
▼33.8%
₹1.9K Cr
▲6.6%
₹1.8K Cr
▲15.6%
₹1.5K Cr
▼22.7%
₹2.0K Cr
▲5.5%
₹1.9K Cr
▲9.9%
₹1.7K Cr
▲30.4%
₹1.3K Cr
OPM
18.0%
▼28.0%
25.0%
▼3.8%
26.0%
▲13.0%
23.0%
▼17.9%
28.0%
▲3.7%
27.0%
▲3.8%
26.0%
▲23.8%
21.0%
Net Profit
₹674 Cr
▼50.2%
₹1.4K Cr
▲4.7%
₹1.3K Cr
▲6.4%
₹1.2K Cr
▼22.9%
₹1.6K Cr
▲20.7%
₹1.3K Cr
▲11.1%
₹1.2K Cr
▲26.1%
₹932 Cr
EPS (₹)
8.37
▼50.0%
16.73
▲4.2%
16.06
▲6.1%
15.13
▼22.2%
19.45
▲20.6%
16.13
▲10.6%
14.58
▲25.4%
11.63

Values in ₹ Cr · Source: Screener.in

Annual Profit & Loss

MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Revenue
₹28.2K Cr
▲2.2%
₹27.5K Cr
▲6.9%
₹25.8K Cr
▲13.3%
₹22.8K Cr
▲4.5%
₹21.8K Cr
▲13.6%
₹19.2K Cr
▲11.8%
₹17.1K Cr
▲4.7%
₹16.4K Cr
▲8.0%
₹15.2K Cr
▲5.3%
₹14.4K Cr
Expenses
₹22.3K Cr
▲9.1%
₹20.4K Cr
▲4.8%
₹19.5K Cr
▲9.9%
₹17.7K Cr
▲3.0%
₹17.2K Cr
▲15.5%
₹14.9K Cr
▲7.0%
₹13.9K Cr
▲5.0%
₹13.3K Cr
▲7.6%
₹12.3K Cr
▲3.6%
₹11.9K Cr
Op. Profit
₹5.9K Cr
▼17.5%
₹7.1K Cr
▲13.3%
₹6.3K Cr
▲25.1%
₹5.0K Cr
▲10.4%
₹4.6K Cr
▲7.1%
₹4.3K Cr
▲32.6%
₹3.2K Cr
▲3.5%
₹3.1K Cr
▲9.6%
₹2.8K Cr
▲13.2%
₹2.5K Cr
OPM
21.0%
▼19.2%
26.0%
▲8.3%
24.0%
▲9.1%
22.0%
▲4.8%
21.0%
▼4.5%
22.0%
▲15.8%
19.0%
▲0.0%
19.0%
▲0.0%
19.0%
▲11.8%
17.0%
Other Income
₹606 Cr
▼29.7%
₹862 Cr
▲56.2%
₹552 Cr
▲88.4%
₹293 Cr
▲196.0%
₹99 Cr
▼62.8%
₹266 Cr
▼22.7%
₹344 Cr
▼27.9%
₹477 Cr
▲70.4%
₹280 Cr
▲34.6%
₹208 Cr
Interest
₹54 Cr
▼12.9%
₹62 Cr
▼31.1%
₹90 Cr
▼18.2%
₹110 Cr
▲3.8%
₹106 Cr
▼34.2%
₹161 Cr
▼18.3%
₹197 Cr
▲17.3%
₹168 Cr
▲47.4%
₹114 Cr
▼28.3%
₹159 Cr
Depreciation
₹1.2K Cr
▲9.4%
₹1.1K Cr
▲5.3%
₹1.1K Cr
▼10.3%
₹1.2K Cr
▲11.4%
₹1.1K Cr
▼1.5%
₹1.1K Cr
▼9.1%
₹1.2K Cr
▼11.4%
₹1.3K Cr
▲0.2%
₹1.3K Cr
▲0.0%
₹1.3K Cr
PBT
₹5.2K Cr
▼23.4%
₹6.8K Cr
▲19.6%
₹5.7K Cr
▲41.2%
₹4.0K Cr
▲15.6%
₹3.5K Cr
▲6.2%
₹3.3K Cr
▲51.1%
₹2.2K Cr
▲4.8%
₹2.1K Cr
▲24.6%
₹1.7K Cr
▲36.6%
₹1.2K Cr
Tax %
26.0%
▲18.2%
22.0%
▼18.5%
27.0%
▼10.0%
30.0%
▲11.1%
27.0%
▲0.0%
27.0%
▼6.9%
29.0%
▲7.4%
27.0%
▲80.0%
15.0%
▲0.0%
15.0%
Net Profit
₹3.9K Cr
▼26.7%
₹5.3K Cr
▲26.8%
₹4.2K Cr
▲46.6%
₹2.8K Cr
▲11.2%
₹2.5K Cr
▲6.6%
₹2.4K Cr
▲59.3%
₹1.5K Cr
▲0.5%
₹1.5K Cr
▲5.3%
₹1.4K Cr
▲36.9%
₹1.0K Cr
EPS (₹)
48.02
▼26.4%
65.28
▲27.9%
51.05
▲47.1%
34.71
▲11.3%
31.19
▲4.6%
29.82
▲55.5%
19.18
▲1.2%
18.96
▲8.2%
17.52
▲40.0%
12.51
Div Payout
27.0%
▲8.0%
25.0%
▲0.0%
25.0%
▲4.2%
24.0%
▲50.0%
16.0%
▼5.9%
17.0%
▼19.0%
21.0%
▲31.3%
16.0%
▼5.9%
17.0%
▲6.3%
16.0%

Values in ₹ Cr · Source: Screener.in

Balance Sheet

ItemSep 2025Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Liabilities
Equity Capital
₹162 Cr
▲0.0%
₹162 Cr
▲0.6%
₹161 Cr
▲0.0%
₹161 Cr
▲0.0%
₹161 Cr
▲0.0%
₹161 Cr
▲0.0%
₹161 Cr
▲0.0%
₹161 Cr
▲0.0%
₹161 Cr
▲0.0%
₹161 Cr
Reserves
₹32.8K Cr
▲5.6%
₹31.0K Cr
▲16.9%
₹26.5K Cr
▲14.2%
₹23.2K Cr
▲12.4%
₹20.7K Cr
▲13.8%
₹18.2K Cr
▲16.4%
₹15.6K Cr
▲5.1%
₹14.9K Cr
▲5.6%
₹14.1K Cr
▲13.6%
₹12.4K Cr
Borrowings
₹467 Cr
▲6.6%
₹438 Cr
▼21.6%
₹559 Cr
▼30.4%
₹803 Cr
▼24.0%
₹1.1K Cr
▼47.6%
₹2.0K Cr
▼28.5%
₹2.8K Cr
▼34.8%
₹4.3K Cr
▲5.3%
₹4.1K Cr
▼0.4%
₹4.1K Cr
Other Liabilities
₹6.8K Cr
▲18.9%
₹5.7K Cr
▲8.3%
₹5.3K Cr
▲3.5%
₹5.1K Cr
▲2.6%
₹5.0K Cr
▲9.9%
₹4.5K Cr
▼6.8%
₹4.8K Cr
▲9.2%
₹4.4K Cr
▲2.0%
₹4.3K Cr
▲3.2%
₹4.2K Cr
Total Liabilities
₹40.2K Cr
▲7.6%
₹37.3K Cr
▲14.8%
₹32.5K Cr
▲11.0%
₹29.3K Cr
▲9.1%
₹26.9K Cr
▲8.1%
₹24.9K Cr
▲6.1%
₹23.4K Cr
▼1.4%
₹23.8K Cr
▲4.8%
₹22.7K Cr
▲8.6%
₹20.9K Cr
Assets
Fixed Assets
₹10.9K Cr
▲9.3%
₹10.0K Cr
▲4.2%
₹9.6K Cr
▲4.9%
₹9.2K Cr
▼5.4%
₹9.7K Cr
▲1.8%
₹9.5K Cr
▼1.7%
₹9.7K Cr
▲0.8%
₹9.6K Cr
▼3.4%
₹9.9K Cr
▲4.8%
₹9.5K Cr
CWIP
₹1.4K Cr
▼8.2%
₹1.6K Cr
▲35.8%
₹1.2K Cr
▲5.5%
₹1.1K Cr
▲42.7%
₹766 Cr
▼20.9%
₹969 Cr
▲17.5%
₹825 Cr
▲22.0%
₹676 Cr
▼31.1%
₹981 Cr
▼41.7%
₹1.7K Cr
Investments
₹8.2K Cr
▲3.6%
₹7.9K Cr
▲45.6%
₹5.4K Cr
▲48.8%
₹3.7K Cr
▲43.6%
₹2.6K Cr
▼5.9%
₹2.7K Cr
▲84.2%
₹1.5K Cr
▼42.4%
₹2.6K Cr
▲102.9%
₹1.3K Cr
▲29.4%
₹973 Cr
Other Assets
₹19.6K Cr
▲9.8%
₹17.8K Cr
▲9.2%
₹16.3K Cr
▲6.1%
₹15.4K Cr
▲11.0%
₹13.9K Cr
▲18.8%
₹11.7K Cr
▲1.9%
₹11.4K Cr
▲4.8%
₹10.9K Cr
▲4.2%
₹10.5K Cr
▲20.2%
₹8.7K Cr
Total Assets
₹40.2K Cr
▲7.6%
₹37.3K Cr
▲14.8%
₹32.5K Cr
▲11.0%
₹29.3K Cr
▲9.1%
₹26.9K Cr
▲8.1%
₹24.9K Cr
▲6.1%
₹23.4K Cr
▼1.4%
₹23.8K Cr
▲4.8%
₹22.7K Cr
▲8.6%
₹20.9K Cr

Values in ₹ Cr · Source: Screener.in

Cash Flow Statement

ItemMar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Operating CF
₹5.0K Cr
▲21.1%
₹4.1K Cr
▲27.7%
₹3.2K Cr
▼2.6%
₹3.3K Cr
▼11.4%
₹3.8K Cr
▲22.4%
₹3.1K Cr
▲81.4%
₹1.7K Cr
▲15.6%
₹1.5K Cr
▼38.6%
₹2.4K Cr
▲36.8%
₹1.7K Cr
Investing CF
₹-3.7K Cr
▼23.5%
₹-3.0K Cr
▼25.5%
₹-2.4K Cr
▼27.9%
₹-1.9K Cr
▲21.7%
₹-2.4K Cr
▼2182.5%
₹114 Cr
▲106.8%
₹-1.7K Cr
▼102.4%
₹-834 Cr
▲36.0%
₹-1.3K Cr
▲71.2%
₹-4.5K Cr
Financing CF
₹-1.3K Cr
▼7.8%
₹-1.2K Cr
▼25.3%
₹-958 Cr
▲40.1%
₹-1.6K Cr
▼29.0%
₹-1.2K Cr
▲58.0%
₹-2.9K Cr
▼745.0%
₹-349 Cr
▲9.4%
₹-385 Cr
▲71.0%
₹-1.3K Cr
▼142.7%
₹3.1K Cr
Net Cash Flow
₹30 Cr
▲161.2%
₹-49 Cr
▲49.5%
₹-97 Cr
▲26.5%
₹-132 Cr
▼193.6%
₹141 Cr
▼39.7%
₹234 Cr
▲167.8%
₹-345 Cr
▼242.0%
₹243 Cr
▲198.0%
₹-248 Cr
▼179.5%
₹312 Cr
Free Cash Flow
₹3.5K Cr
▲23.8%
₹2.8K Cr
▲34.1%
₹2.1K Cr
▼20.5%
₹2.6K Cr
▼10.8%
₹3.0K Cr
▲42.3%
₹2.1K Cr
▲75.5%
₹1.2K Cr
▲64.2%
₹723 Cr
▼43.7%
₹1.3K Cr
▲86.6%
₹688 Cr

Values in ₹ Cr · Source: Screener.in

Key Ratios History

MetricMar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Debtor Days
73d
▲7.4%
68d
▲4.6%
65d
▲14.0%
57d
▼13.6%
66d
▼20.5%
83d
▼10.8%
93d
▲24.0%
75d
▲15.4%
65d
▲4.8%
62d
Inventory Days
231d
▲6.5%
217d
▼4.8%
228d
▼0.9%
230d
▼0.9%
232d
▼13.1%
267d
▲6.8%
250d
▼7.7%
271d
▲13.4%
239d
▼12.5%
273d
Days Payable
116d
▲13.7%
102d
▼8.9%
112d
▲3.7%
108d
▲4.9%
103d
▼25.9%
139d
▲13.0%
123d
▼13.4%
142d
▲31.5%
108d
▲1.9%
106d
Cash Conv. Cycle
188d
▲3.3%
182d
▲0.6%
181d
▲0.6%
180d
▼7.7%
195d
▼7.6%
211d
▼4.1%
220d
▲7.8%
204d
▲4.1%
196d
▼14.8%
230d
Working Capital Days
128d
▲6.7%
120d
▲6.2%
113d
▲18.9%
95d
▲1.1%
94d
▼16.8%
113d
▼14.4%
132d
▲11.9%
118d
▲19.2%
99d
▲1090.0%
-10d
ROCE
23.0%
▲0.0%
23.0%
▲27.8%
18.0%
▲5.9%
17.0%
▲0.0%
17.0%
▲41.7%
12.0%
▲9.1%
11.0%
▲22.2%
9.0%
▲28.6%
7.0%
▼46.2%
13.0%

Source: Screener.in · Lower days = better efficiency

Deep Dive Analysis

Option Chain
Strike-wise OI & IV
OI Analysis
PCR, buildup type
FII / DII
Institutional flows
Max Pain
Writer pain levels

About Cipla Limited

Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs[1]

Healthcare · Pharmaceuticals & Biotechnology

Related Analysis

Same Sector

ALKEM
Alkem Laboratories Limited
Neutral
APOLLOHOSP
Apollo Hospitals Enterprise Limited
Neutral
AUROPHARMA
Aurobindo Pharma Limited
Neutral
BIOCON
Biocon Limited
Neutral
DIVISLAB
Divi's Laboratories Limited
Neutral

Frequently Asked Questions

What is Cipla Limited share price today?▾
Cipla Limited (CIPLA) is currently trading at ₹1,416 on NSE, as of the last market session. Prices update daily after market close on MarketNetra.
Is Cipla Limited available in F&O (Futures & Options)?▾
Yes, Cipla Limited (CIPLA) is part of the NSE F&O segment with a lot size of 375 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Cipla Limited 52-week high and low?▾
Cipla Limited's 52-week high is ₹1,673 and the 52-week low is ₹1,166. The current price of ₹1,416 is 15.4% below the 52W high.
What is Cipla Limited P/E ratio?▾
Cipla Limited's current P/E ratio is 30.1. This indicates the market is paying ₹30.1 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Cipla Limited options?▾
Cipla Limited options are traded on NSE with monthly expiry contracts (lot size: 375 shares). To trade CIPLA options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.